Literature DB >> 19645785

Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research.

Umberto Veronesi1, Stefano Zurrida, Giuseppe Viale, Viviana Galimberti, Paolo Arnone, Franco Nolè.   

Abstract

The TNM(UICC) classification of breast cancer categorizes tumor size, regional lymph node involvement, and distant metastases. Treatment is influenced by these characteristics, but requires knowledge of several other factors. In fact, effective treatment is dependent on disease extent, hormone receptor status, and other biologic characteristics of the cancer. We propose a new classification [tumor node metastasis (TNM)] that not only includes relevant biologic characteristics and can expand to include others as they are validated but also specifies tumor size exactly (T2.3 indicates a cancer of maximum diameter 2.3 cm), provides more information on regional lymph node involvement, and specifies the site(s) of distant metastases. We also propose abolishing the term "carcinoma" for non-invasive neoplastic conditions and the term "infiltrating" for carcinomas. The new classification is sufficiently similar to the TNM(UICC) classification to permit valid comparison of patients classified by both systems, but is more logical, provides information useful for guiding therapy, and is flexible enough to satisfy present and future clinical and research needs.

Entities:  

Mesh:

Year:  2009        PMID: 19645785     DOI: 10.1111/j.1524-4741.2009.00719.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  21 in total

1.  Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop.

Authors:  Ann H Partridge; Joann G Elmore; Debbie Saslow; Worta McCaskill-Stevens; Stuart J Schnitt
Journal:  CA Cancer J Clin       Date:  2012-04-04       Impact factor: 508.702

2.  The TNM classification of breast cancer: need for change.

Authors:  Paolo Arnone; Stefano Zurrida; Giuseppe Viale; Silvia Dellapasqua; Emilia Montagna; Paola Arnaboldi; Mattia Intra; Umberto Veronesi
Journal:  Updates Surg       Date:  2010-10

3.  Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.

Authors:  Mariana Chavez-MacGregor; Elizabeth A Mittendorf; Christina A Clarke; Daphne Y Lichtensztajn; Kelly K Hunt; Sharon H Giordano
Journal:  Oncologist       Date:  2017-06-07

4.  Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system.

Authors:  Min Yi; Elizabeth A Mittendorf; Janice N Cormier; Thomas A Buchholz; Karl Bilimoria; Aysegul A Sahin; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo; Sheng Luo; Aman U Buzdar; Jaime R Crow; Henry M Kuerer; Kelly K Hunt
Journal:  J Clin Oncol       Date:  2011-11-14       Impact factor: 44.544

5.  Strong Correlation of MTHFR Gene Polymorphisms with Breast Cancer and its Prognostic Clinical Factors among Egyptian Females.

Authors:  Moataza H Omran; Basma E Fotouh; Wafaa G Shousha; Abeer Ismail; Noha E Ibrahim; Shimaa S Ramadan
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

6.  Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy.

Authors:  San-Gang Wu; Qun Li; Juan Zhou; Jia-Yuan Sun; Feng-Yan Li; Qin Lin; Huan-Xin Lin; Xun-Xing Gaun; Zhen-Yu He
Journal:  Cancer Res Treat       Date:  2014-12-08       Impact factor: 4.679

7.  Lymph node ratio may predict the benefit of postoperative radiotherapy in node-positive cervical cancer.

Authors:  Juan Zhou; Qiong-Hua Chen; San-Gang Wu; Zhen-Yu He; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Ke-Li You
Journal:  Oncotarget       Date:  2016-05-17

8.  Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel.

Authors:  Aliakbar Taherian; Tahereh Mazoochi
Journal:  Iran J Basic Med Sci       Date:  2012-01       Impact factor: 2.699

9.  Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy.

Authors:  San-Gang Wu; Yong Chen; Jia-Yuan Sun; Feng-Yan Li; Qin Lin; Huan-Xin Lin; Zhen-Yu He
Journal:  Radiat Oncol       Date:  2013-05-14       Impact factor: 3.481

10.  Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

Authors:  Yun Yeong Kim; Heung Kyu Park; Kyung Hee Lee; Kwan Il Kim; Yong Soon Chun
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.